- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 785317, 11 pages
New Insights into the Role of the Immune Microenvironment in Breast Carcinoma
1Clinical Oncology Department, Hospital Universitario Virgen Macarena, Avenida Dr. Fedriani s/n, 41009 Sevilla, Spain
2Biochemistry Department, Hospital Universitario Virgen Macarena, Avenida Dr. Fedriani s/n, 41009 Sevilla, Spain
3Pathology Department, Hospital Universitario Virgen Macarena, Avenida Dr. Fedriani s/n, 41009 Sevilla, Spain
4Clinical Oncology Department, Hospital Universitario Virgen del Rocío, Avenida Manuel Siurot s/n, 41013 Sevilla, Spain
5Statistics Department, Universidad de Sevilla, Avenida Dr. Fedriani s/n, 41009 Sevilla, Spain
6Clinical Oncology Department, Hospital Universitario Virgen de la Victoria, Campus de Teatinos s/n, 29010 Málaga, Spain
7Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pío XII 55, 31008 Pamplona, Spain
Received 29 January 2013; Accepted 14 April 2013
Academic Editor: Arnon Nagler
Copyright © 2013 Luis de la Cruz-Merino et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. Demaria, M. D. Volm, R. L. Shapiro et al., “Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy,” Clinical Cancer Research, vol. 7, no. 10, pp. 3025–3030, 2001.
- C. Denkert, S. Loibl, A. Noske et al., “Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 105–113, 2010.
- M. Schmidt, D. Bohm, C. von Torne, et al., “The humoral immune system has a key prognostic impact in node-negative breast cancer,” Cancer Research, vol. 68, pp. 5405–5413, 2008.
- S. Ladoire, L. Arnould, L. Apetoh et al., “Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating Foxp3+ regulatory T cells,” Clinical Cancer Research, vol. 14, no. 8, pp. 2413–2420, 2008.
- S. A. Perez, M. V. Karamouzis, D. V. Skarlos et al., “CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients,” Clinical Cancer Research, vol. 13, no. 9, pp. 2714–2721, 2007.
- S. M. A. Mahmoud, E. C. Paish, D. G. Powe et al., “Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer,” Journal of Clinical Oncology, vol. 29, no. 15, pp. 1949–1955, 2011.
- J. B. A. G. Haanen, A. Baars, R. Gomez et al., “Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients,” Cancer Immunology, Immunotherapy, vol. 55, no. 4, pp. 451–458, 2006.
- F. Pages, A. Berger, M. Camus, et al., “Effector memory T cells, early metastasis, and survival in colorectal cancer,” The New England Journal of Medicine, vol. 353, pp. 2654–2666, 2005.
- L. Zhang, J. R. Conejo-Garcia, D. Katsaros, et al., “Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer,” The New England Journal of Medicine, vol. 348, pp. 203–213, 2003.
- J. Galon, A. Costes, F. Sanchez-Cabo et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006.
- H. Nishikawa and S. Sakaguchi, “Regulatory T cells in tumor immunity,” International Journal of Cancer, vol. 127, no. 4, pp. 759–767, 2010.
- S. Yamagiwa, J. D. Gray, S. Hashimoto, and D. A. Horwitz, “A role for TGF-β in the generation and expansion of CD4+CD25+ regulatory t cells from human peripheral blood,” Journal of Immunology, vol. 166, no. 12, pp. 7282–7289, 2001.
- J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, “Foxp3 programs the development and function of CD4+CD25+ regulatory T cells,” Nature Immunology, vol. 4, pp. 330–336, 2003.
- S. Hori, T. Nomura, and S. Sakaguchi, “Control of regulatory T cell development by the transcription factor Foxp3,” Science, vol. 299, no. 5609, pp. 1057–1061, 2003.
- M. A. Gavin, J. P. Rasmussen, J. D. Fontenot et al., “Foxp3-dependent programme of regulatory T-cell differentiation,” Nature, vol. 445, no. 7129, pp. 771–775, 2007.
- Y. Zheng, S. Z. Josefowicz, A. Kas, T. T. Chu, M. A. Gavin, and A. Y. Rudensky, “Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells,” Nature, vol. 445, no. 7130, pp. 936–940, 2007.
- D. A. A. Vignali, L. W. Collison, and C. J. Workman, “How regulatory T cells work,” Nature Reviews Immunology, vol. 8, no. 7, pp. 523–532, 2008.
- L. W. Collison, M. R. Pillai, V. Chaturvedi, and D. A. A. Vignali, “Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner,” Journal of Immunology, vol. 182, no. 10, pp. 6121–6128, 2009.
- L. De la Cruz-Merino, F. Henao-Carrasco, T. García-Manrique, et al., “Role of transforming growth factor beta in cancer microenvironment,” Clinical and Translational Oncology, vol. 11, no. 11, pp. 715–720, 2009.
- G. J. Bates, S. B. Fox, C. Han et al., “Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse,” Journal of Clinical Oncology, vol. 24, no. 34, pp. 5373–5380, 2006.
- A. Balsari, A. Merlo, P. Casalini et al., “FOXP3 expression and overall survival in breast cancer,” Journal of Clinical Oncology, vol. 27, no. 11, pp. 1746–1752, 2009.
- S. Ladoire, G. Mignot, C. Dalban, et al., “FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial,” Annals of Oncology, vol. 23, pp. 2552–2256, 2012.
- S. Ladoire, L. Arnould, G. Mignot et al., “Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy,” Breast Cancer Research and Treatment, vol. 125, no. 1, pp. 65–72, 2011.
- A. M. Wolf, D. Wolf, M. Steurer, G. Gastl, E. Gunsilius, and B. Grubeck-Loebenstein, “Increase of regulatory T cells in the peripheral blood of cancer patients,” Clinical Cancer Research, vol. 9, no. 2, pp. 606–612, 2003.
- U. K. Liyanage, T. T. Moore, H. G. Joo et al., “Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma,” Journal of Immunology, vol. 169, no. 5, pp. 2756–2761, 2002.
- A. K. Abbas, A. H. Lichtman, and S. Pillai, “Immunity to tumors,” in Cellular and Molecular Immunology, A. K. Abbas, A. H. Lichtman, and S. Pillai, Eds., pp. 397–417, Saunders Elsevier, Philadelphia, Pa, USA, 6th edition, 2007.
- A. H. Sharpe and A. K. Abbas, “T-cell costimulation—biology, therapeutic potential, and challenges,” The New England Journal of Medicine, vol. 355, no. 10, pp. 973–975, 2006.
- E. Fonsatti, M. Maio, M. Altomonte, and P. Hersey, “Biology and clinical applications of CD40 in cancer treatment,” Seminars in Oncology, vol. 37, no. 5, pp. 517–523, 2010.
- I. S. Grewal and R. A. Flavell, “CD40 and CD154 in cell-mediated immunity,” Annual Review of Immunology, vol. 16, pp. 111–135, 1998.
- G. P. Dunn, L. J. Old, and R. D. Schreiber, “The immunobiology of cancer immunosurveillance and immunoediting,” Immunity, vol. 21, no. 2, pp. 137–148, 2004.
- L. De La Cruz-Merino, E. Grande-Pulido, A. Albero-Tamarit, and M. E. C. M. De Villena, “Cancer and immune response: old and new evidence for future challenges,” Oncologist, vol. 13, no. 12, pp. 1246–1254, 2008.
- H. Mao, L. Zhang, Y. Yang et al., “New insights of CTLA-4 into its biological function in breast cancer,” Current Cancer Drug Targets, vol. 10, no. 7, pp. 728–736, 2010.
- T. Azuma, S. Yao, G. Zhu, A. S. Flies, et al., “B7-H1 is a ubiquitous anti-apoptotic receptor on cancer cells,” Blood, vol. 111, pp. 3635–3643, 2008.
- V. V. Parekh, S. Lalani, S. Kim et al., “PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells,” Journal of Immunology, vol. 182, no. 5, pp. 2816–2826, 2009.
- J. Weber, “Immune checkpoint proteins: a new therapeutic paradigm for cancerpreclinical background: CTLA-4 and PD-1 blockade,” Seminars in Oncology, vol. 37, no. 5, pp. 430–439, 2010.
- H. Ghebeh, S. Mohammed, A. Al-Omair et al., “The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors,” Neoplasia, vol. 8, no. 3, pp. 190–198, 2006.
- S. M. Jensen, L. D. Maston, M. J. Gough et al., “Signaling through OX40 enhances antitumor immunity,” Seminars in Oncology, vol. 37, no. 5, pp. 524–532, 2010.
- W. L. Redmond, C. E. Ruby, and A. D. Weinberg, “The role of OX40-mediated co-stimulation in T-cell activation and survival,” Critical Reviews in Immunology, vol. 29, pp. 187–201, 2009.
- C. E. Ruby, R. Montler, R. Zheng, S. Shu, and A. D. Weinberg, “IL-12 is required for anti-OX40-mediated CD4 T cell survival,” Journal of Immunology, vol. 180, no. 4, pp. 2140–2148, 2008.
- S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and cancer,” Cell, vol. 140, no. 6, pp. 883–899, 2010.
- S. Ostrand-Rosenberg and P. Sinha, “Myeloid-derived suppressor cells: linking inflammation and cancer,” Journal of Immunology, vol. 182, no. 8, pp. 4499–4506, 2009.
- K. Movahedi, D. Laoui, C. Gysemans et al., “Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes,” Cancer Research, vol. 70, no. 14, pp. 5728–5739, 2010.
- B. F. Zamarron and W. Chen, “Dual roles of immune cells and their factors in cancer development and progression,” International Journal of Biological Sciences, vol. 7, no. 5, pp. 651–658, 2011.
- S. K. Biswas and A. Mantovani, “Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm,” Nature Immunology, vol. 11, no. 10, pp. 889–896, 2010.
- G. Khramtsova, C. Liao, and A. Khramtsov, “The M2/alternatively activated macrophage phenotype correlates with aggressive histopathologic features and poor clinical outcome in early stage breast cancer,” Cancer Research, vol. 69, 24 Supplement, Abstract 107, 2009.
- S. Nagaraj and D. I. Gabrilovich, “Myeloid-derived suppressor cells in human cancer,” Cancer Journal, vol. 16, no. 4, pp. 348–353, 2010.
- D. I. Gabrilovich and S. Nagaraj, “Myeloid-derived suppressor cells as regulators of the immune system,” Nature Reviews Immunology, vol. 9, no. 3, pp. 162–174, 2009.
- S. Cole, A. Montero, E. Garret-Mayer, et al., “Elevated circulating myeloid derived suppressor cells (MDSC) are associated with inferior overall survival and correlate with circulating tumor cells (CTC) in patients with metastatic breast cancer,” Cancer Research, vol. 69, 24 Supplement, Abstract 4135, 2009.
- W. Chen, W. Jin, N. Hardegen et al., “Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3,” Journal of Experimental Medicine, vol. 198, no. 12, pp. 1875–1886, 2003.
- W. W. Lin and M. Karin, “A cytokine-mediated link between innate immunity, inflammation, and cancer,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1175–1183, 2007.
- E. K. Waller, “The role of sargramostim (rhGM-CSF) as immunotherapy,” Oncologist, vol. 12, no. 2, pp. 22–26, 2007.
- L. E. Spitler, M. L. Grossbard, M. S. Ernstoff et al., “Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor,” Journal of Clinical Oncology, vol. 18, no. 8, pp. 1614–1621, 2000.
- P. Correale, M. G. Cusi, K. Y. Tsang et al., “Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients,” Journal of Clinical Oncology, vol. 23, no. 35, pp. 8950–8958, 2005.
- A. H. Honkoop, S. A. Luykx-De Barker, K. Hoekman et al., “Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer,” Oncologist, vol. 4, no. 2, pp. 106–111, 1999.
- H. M. Pinedo, T. D. De Gruijl, E. Van Der Wall, and J. Buter, “Biological concepts of prolonged neoadjuvant treatment plus GM-CSF in locally advanced tumors,” Oncologist, vol. 5, no. 6, pp. 497–500, 2000.
- M. E. C. Lutsiak, R. T. Semnani, R. De Pascalis, S. V. S. Kashmiri, J. Schlom, and H. Sabzevari, “Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide,” Blood, vol. 105, no. 7, pp. 2862–2868, 2005.
- F. Ghiringhelli, C. Menard, P. E. Puig et al., “Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients,” Cancer Immunology, Immunotherapy, vol. 56, no. 5, pp. 641–648, 2007.
- P. Attia, A. V. Maker, L. R. Haworth, L. Rogers-Freezer, and S. A. Rosenberg, “Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma,” Journal of Immunotherapy, vol. 28, no. 6, pp. 582–592, 2005.
- M. T. Litzinger, R. Fernando, T. J. Curiel, D. W. Grosenbach, J. Schlom, and C. Palena, “IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity,” Blood, vol. 110, no. 9, pp. 3192–3201, 2007.
- T. J. Curiel, “Regulatory T cells and treatment of cancer,” Current Opinion in Immunology, vol. 20, no. 2, pp. 241–246, 2008.
- K. Wing, Y. Onishi, P. Prieto-Martin et al., “CTLA-4 control over Foxp3+ regulatory T cell function,” Science, vol. 322, no. 5899, pp. 271–275, 2008.
- K. S. Peggs, S. A. Quezada, C. A. Chambers, A. J. Korman, and J. P. Allison, “Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies,” Journal of Experimental Medicine, vol. 206, no. 8, pp. 1717–1725, 2009.
- S. Khan, D. J. Burt, C. Ralph, F. C. Thistlethwaite, R. E. Hawkins, and E. Elkord, “Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells,” Clinical Immunology, vol. 138, no. 1, pp. 85–96, 2011.
- C. Robert and F. Ghiringhelli, “What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?” Oncologist, vol. 14, no. 8, pp. 848–861, 2009.
- F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010.
- C. Robert, L. Thomas, I. Bondarenko et al., “Ipilimumab plus dacarbazine for previously untreated metastatic melanoma,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2517–2526, 2011.
- L. Calabr, R. Danielli, L. Sigalotti, and M. Maio, “Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications,” Seminars in Oncology, vol. 37, no. 5, pp. 460–467, 2010.
- R. Vonderheide, P. M. LoRusso, M. Khalil, et al., “Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of ICOS expression on patient T cells,” Clinical Cancer Research, vol. 16, pp. 3485–3494, 2010.
- A. A. Tarhini and F. Iqbal, “CTLA-4 blockade: therapeutic potential in cancer treatments,” OncoTargets and Therapy, vol. 3, pp. 15–25, 2010.
- M. A. Curran, W. Montalvo, H. Yagita, and J. P. Allison, “PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 9, pp. 4275–4280, 2010.
- J. R. Brahmer, C. G. Drake, I. Wollner et al., “Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates,” Journal of Clinical Oncology, vol. 28, no. 19, pp. 3167–3175, 2010.
- E. M. Sotomayor, I. Borrello, E. Tubb et al., “Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of cd40,” Nature Medicine, vol. 5, no. 7, pp. 780–787, 1999.
- L. Diehl, A. T. Den Boer, S. P. Schoenberger et al., “CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy,” Nature Medicine, vol. 5, no. 7, pp. 774–779, 1999.
- G. L. Beatty, E. G. Chiorean, M. P. Fishman et al., “CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans,” Science, vol. 331, no. 6024, pp. 1612–1616, 2011.
- K. Takeda, Y. Kojima, T. Uno et al., “Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules,” Journal of Immunology, vol. 184, no. 10, pp. 5493–5501, 2010.
- S. Murata, B. H. Ladle, P. S. Kim et al., “OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen,” Journal of Immunology, vol. 176, no. 2, pp. 974–983, 2006.
- D. Hirschhorn-Cymerman, G. A. Rizzuto, T. Merghoub et al., “OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis,” Journal of Experimental Medicine, vol. 206, no. 5, pp. 1103–1116, 2009.
- M. J. Gough, M. R. Crittenden, M. Sarff et al., “Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice,” Journal of Immunotherapy, vol. 33, no. 8, pp. 798–809, 2010.
- J. D. Wolchok, A. Hoos, S. O’Day, et al., “Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria,” Clinical Cancer Research, vol. 15, pp. 7412–7420, 2009.
- L. Zitvogel, L. Apetoh, F. Ghiringhelli, F. André, A. Tesniere, and G. Kroemer, “The anticancer immune response: indispensable for therapeutic success?” Journal of Clinical Investigation, vol. 118, no. 6, pp. 1991–2001, 2008.
- L. Apetoh, F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz, et al., “Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy,” Nature Medicine, vol. 13, pp. 1050–1059, 2007.
- M. Obeid, A. Tesniere, T. Panaretakis, R. Tufi, N. Joza, et al., “Ecto-calreticulin in immunogenic chemotherapy,” Immunological Reviews, vol. 220, pp. 22–34, 2007.
- A. K. Nowak, B. W. S. Robinson, and R. A. Lake, “Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors,” Cancer Research, vol. 63, no. 15, pp. 4490–4496, 2003.
- N. Casares, M. O. Pequignot, A. Tesniere et al., “Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death,” Journal of Experimental Medicine, vol. 202, no. 12, pp. 1691–1701, 2005.
- N. M. Haynes, R. G. van der Most, R. A. Lake, and M. J. Smyth, “Immunogenic anti-cancer chemotherapy as an emerging concept,” Current Opinion in Immunology, vol. 20, no. 5, pp. 545–557, 2008.
- A. Tesniere, L. Apetoh, F. Ghiringhelli et al., “Immunogenic cancer cell death: a key-lock paradigm,” Current Opinion in Immunology, vol. 20, no. 5, pp. 504–511, 2008.
- R. A. Lake and B. W. S. Robinson, “Immunotherapy and chemotherapy-a practical partnership,” Nature Reviews Cancer, vol. 5, pp. 397–405, 2005.
- E. Suzuki, V. Kapoor, A. S. Jassar, L. R. Kaiser, and S. M. Albelda, “Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity,” Clinical Cancer Research, vol. 11, no. 18, pp. 6713–6721, 2005.
- R. A. Lake and R. G. van der Most, “A better way for a cancer cell to die,” The New England Journal of Medicine, vol. 354, pp. 2503–2504, 2006.
- D. Rüttinger, H. Winter, N. K. Van Den Engel et al., “Immunotherapy of cancer: key findings and commentary on the third tegernsee conference,” Oncologist, vol. 15, no. 1, pp. 112–118, 2010.
- C. R. Flowers, R. Sinha, and J. M. Vose, “Improving outcomes for patients with diffuse large B-cell lymphoma,” CA Cancer Journal for Clinicians, vol. 60, no. 6, pp. 393–408, 2010.
- V. Guarneri, E. Barbieri, M. V. Dieci, F. Piacentini, and P. Conte, “Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer,” Cancer Treatment Reviews, vol. 36, no. 3, pp. S62–S66, 2010.
- E. A. Mittendorf, C. E. Storrer, C. D. Shriver, S. Ponniah, and G. E. Peoples, “Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer,” Annals of Surgical Oncology, vol. 13, no. 8, pp. 1085–1098, 2006.